EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review

Giuliana Ciappina iD, Enrica Toscano iD, Alessandro Ottaiano iD, Maurizio Capuozzo iD, Pierluigi Consolo, Enrica Maiorana, Patrizia Carroccio, Tindara Franchina iD, Antonio Ieni iD, Annabella Di Mauro iD, Massimiliano Berretta iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26052216 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Giuliana Ciappina und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, AOU "G. Martino" Hospital, University of Messina, 98125 Messina, Italy. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with metastatic disease posing significant therapeutic challenges. While anti-EGFR therapy has improved outcomes for patients with RAS and BRAF wild-type tumors, resistance remains a major hurdle, limiting treatment efficacy. The concept of negative hyperselection has emerged as a refinement of molecular profiling, identifying additional genomic alterations—such as HER2 and MET amplificationsand MAP2K1 mutations—that predict resistance to anti-EGFR agents. Studies incorporating these expanded assessments have demonstrated that nearly half of patients with RAS/BRAF wild-type tumors harbor alternative resistance biomarkers, underscoring the need for expanded selection criteria. Liquid biopsies, particularly circulating tumor DNA (ctDNA) analysis, have revolutionized precision oncology by providing a minimally invasive, real-time assessment of tumor dynamics. ctDNA-based hyperselection enables the detection of resistance-associated alterations, guiding treatment decisions with greater accuracy than conventional tissue biopsies. Recent trials support the predictive value of ctDNA-defined negative hyperselection, revealing superior outcomes for patients stratified through liquid biopsy. This narrative review explores the evolving role of molecular hyperselection in first-line anti-EGFR therapy, emphasizing the integration of ctDNA to refine patient selection, enhance therapeutic efficacy, and pave the way for personalized treatment strategies in metastatic CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsProtein Kinase InhibitorsHumansErbB ReceptorsBiomarkers, TumorDrug Resistance, NeoplasmCirculating Tumor DNANeoplasm MetastasisMutationLiquid Biopsy

Stichwörter der Autor:innen

BRAFRASanti-EGFR treatmentliquid biopsymetastatic colorectal cancernegative hyperselectionnext generation sequencing

Substanzen

ErbB ReceptorsBiomarkers, TumorEGFR protein, humanCirculating Tumor DNAProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Medical Oncology, AOU "G. Martino" Hospital, University of Messina, 98125 Messina, Italy.
  • School of Specialization in Medical Oncology, Department of Human Pathology "G. Barresi", University of Messina, 98125 Messina, Italy.
  • Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Via M. Semmola, 80131 Naples, Italy.
  • Pharmaceutical Department, Asl Napoli 3 Sud, Marittima Street 3, 80056 Ercolano, Italy.
  • Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
  • Department of Human Pathology of Adult and Childhood "Gaetano Barresi", University of Messina, 98121 Messina, Italy.

ORCID-Profile: Giuliana Ciappina, Enrica Toscano, Alessandro Ottaiano, Maurizio Capuozzo, Tindara Franchina, Antonio Ieni, Annabella Di Mauro, Massimiliano Berretta

Zitieren

APA

Ciappina, G., Toscano, E., Ottaiano, A., Capuozzo, M., Consolo, P., Maiorana, E., Carroccio, P., Franchina, T., Ieni, A., Di Mauro, A., & Berretta, M. (2025). Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26052216

Vancouver

Ciappina G, Toscano E, Ottaiano A, Capuozzo M, Consolo P, Maiorana E, et al. Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26052216

BibTeX
@article{Ciappina2025,
  author = {Ciappina, Giuliana and Toscano, Enrica and Ottaiano, Alessandro and Capuozzo, Maurizio and Consolo, Pierluigi and Maiorana, Enrica and Carroccio, Patrizia and Franchina, Tindara and Ieni, Antonio and Di Mauro, Annabella and Berretta, Massimiliano},
  title = {Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26052216}
}
Kostenlos starten →